12 бет - Ең жақсы Бір бөлімнің МРТ сынағы дәрігерлері - ЖОҒ-515 дәрігерлер

1997 - 2002 Ыстамбұл университетінің Джеррахпаша медицина факультеті, ортопедия және травматология бөлімі

1990 - 1996 Ыстамбұл университетінің Джеррахпаша медицина факультеті

Оның жазған және үлес қосқан мақалалары;

Перинденезді тромбоциттерге бай плазма инъекциясының тендинопатияларды емдеудегі клиникалық тиімділігі: ретроспективті зерттеу Айбарс Кыврак* (а), Мехмет Джан Үнлу (а), Эшреф Терзи (а), Олгар Бирсель (б), Дорук Акгүн (с), Юсуф Пиринджи (д), Гөкхан Кайнак (а), Ысык Акгүн (e)ацетабулярлы сүйек жетіспеушілігі бар науқастарда ацетабулярлы ревизияда ацетабулярлы төбе сақинасы мен Бурч-Шнайдер анти-протузио торының орта және ұзақ мерзімді әсерлері хат-хабар: Юсуф Пиринджи, Мұхаммед Таха Демир, Мүәммәт Сәлі, Фахри Ердоған, Нежат Гүней

Дамыған ересек жамбас дисплазиясындағы проксималды жамбас сүйегінің өлшемдік өзгермелілері Crowe IV түріндегі жамбасы бар пациенттер үшін конустық, тікбұрышты, престеу дизайны оңтайлы таңдау болуы мүмкін екенін көрсетеді

Мамандандырулар

Аяқ-қолды ұзартыу 

Спорттық хирургия

Менискус жыртылуы

Алдыңғы айқас байламының жыртылуы

Тізе протезі

Жамбас протезі

Иық протезі

Иық слапын қалпына келтіру

Биіктігін ұлғайту

Ісік хирургиясы

Аяқ хирургиясы (Hallux Valgus)

Қант диабеттік аяқ

Сүйек инфекциялары (Остеомиелит)

Prof. İbrahim Azboy, M.D.

Languages: English, Kurdish, Arabic

Orthopaedics and Traumatology
 

Areas of Expertise and Interest

• Hip & knee arthroplasty (primary, revision, robotic‑assisted)
• Infection prevention & management in joint replacements
• Minimally invasive and joint‑preserving orthopedic surgery
• Sports & trauma-related injuries (e.g. ACL, fractures)
• Osteoarthritis, cartilage damage & osteonecrosis

International Researcher IDs:  

• ORCID: 0000-0003-0926-3029 / Yoksis Researcher ID: 145243 

Education & Training

• 1994–2001: Hacettepe University, Faculty of Medicine
• 2002–2008: Ministry of Health Istanbul Training and Research Hospital
• 2014 & 2017: Hospital for Special Surgery, New York, USA – Knee and Hip Arthroplasty and Arthroscopy Training
• 2016: Rothman Institute, Thomas Jefferson University, Philadelphia, USA – Knee and Hip Arthroplasty and Hip Preserving Surgery Training

Academic & Professional Appointments

• 2021–Present: Professor, Istanbul Medipol University
• 2017–2020: Associate Professor, Istanbul Medipol University
• 2011–2017: Assistant Professor, Dicle University
• 2008–2011: Consultant MD, Şanlıurfa and Balıkesir Military Hospitals

Professional Memberships

• Member of 9 national and international orthopedic associations including:
  AAHKS, SICOT, EHS, KADAD, TOTBID, TOTEK, and TTB

Scientific & Educational Contributions

• Prof. Dr. İbrahim Azboy has authored over 70 internationally and 25 nationally peer-reviewed journal articles, contributed to 4 book chapters and 2 book translations, and presented at 25+ international and 65+ national congresses. He also serves as a reviewer for 13 scientific journals, including JBJS, JOA, SICOT-J, and JORR.

Teaching & Speaking Engagements

• Speaker/trainer in 20+ national courses and congresses on topics such as:
• Hip and knee arthroplasty
• Prosthetic joint infections
• VTE prophylaxis
• Surgical approaches and implant strategies

Dr. Jirachai Pisutbenya is a spine surgeon. He specializes in endoscopic and minimally invasive spine surgery. He also treats adult spinal deformity and cervical spine disorders.

Accreditations: MD, Faculty of Medicine Ramathibodi Hospital, Mahidol University (2007). Orthopedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University (2014). Spinal Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University (2018).

Experience

2017
Private Nisa Hospital

2011 - 2017
Yenibosna Private Ilke Hospital

2007 - 2011
Gaziosmanpaşa Private Bilge Hospital

Education

2005
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Ear, Nose, and Throat Diseases

2005
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Ear, Nose, and Throat Diseases

2000
İstanbul University Faculty of Medicine, Medical Education

2000
İstanbul University Faculty of Medicine, Medical Education

Dr. Javier Albiñana Silveti is a specialist in orthopedic surgery and pediatric traumatology. He has over 38 years of experience in the treatment of hip dysplasia, bone tumors, malformations and Perthes disease.

Experience

2013 – present | Pediatric Traumatology at the Ruber Internacional and Quirón Hospital in Pozuelo.

2004-2013|Head of the Department of Pediatric Orthopedics at the La Paz Hospital in Madrid.

1994-2004| Assistant in pediatric orthopedics at the Niño Jesus Hospital in Madrid

1992-1994 | Fellow, Department of Pediatric Orthopedics, University of Iowa (USA)

1988-1989|Research Fellow in Paediatric Orthopaedics, Oxford University (UK).

Qualification

1988 | Doctor of Medicine, Autonomous University of Madrid.

1982 | Graduated from the Faculty of Medicine of the Autonomous University of Madrid.

Education:

2004|Associate Professor of the Faculty of Medicine of the UAM.

Publications

2019|Does femoral head orientation influence acetabular development? An experimental study in Lamb. J Pediatr Orthop. 2019 Sep;39(8):416–421.

2015|Pavlik harness outcomes in Ortolani-positive hips: predictors of failure and arthrographic findings. J Child Orthop 2015 Aug;9(4):249-53.

2013|Selective triradiate epiphysiodesis for the treatment of residual experimental acetabular dysplasia. J Pediatr Orthop. 2013 Dec;33(8):821-8.

Communications and presentations

2021|Perthes Disease. Congress of Pediatric Orthopedics, SEOT, Ecuador.

2019|Dysplasia of the hip, Children's Hospital, San Jose, Costa Rica, April 2019

2018| Cerebral Palsy, ASFAPE, Madrid.

2007 | Tear and Dysplasia of the Hip, POSNA, San Diego.

2005 | Open reduction failure and DDH. Boston, IPOTT.

Experience

2019 – 2019

• University of Insubria, Varese, Italy, 

Insubria University Faculty of Medicine

2015

• MERSİN UNIVERSITY/FACULTY OF MEDICINE, DOCTOR, LECTURER

2013 – 2015

• ANKARA PRIVATE ACIBADEM HOSPITAL

2010 – 2012

• DIYARBAKIR TRAINING AND RESEARCH HOSPITAL,

2002 – 2003

• AYDIN 1ST PRIVATE TRAINING BATTALION
•  

Education

2010

• ANKARA UNIVERSITY FACULTY OF MEDICINE, BRAIN AND SURGERY SPECIALIST

1992

• GAZI UNIVERSITY, FACULTY OF MEDICINE

Кәсіби тәжірибе

2006 жылдан бері Мадридтегі Quironsalud Университеттік Ауруханасының және Ruber Juan Bravo Ауруханасының Неврология бөлімінің бастығы болып қызмет атқарады.

Мадридтегі Еуропалық Университеттің Биомедициналық Ғылымдар факультетінің Медицина профессоры, Медицина Ғылымдары Профессорының ұлттық аккредитациясына ие (ANECA-дан берілген).

Медицина докторы, Мадридтегі Complutense университеті (UCM). Көрнекті докторлық диссертацияға арналған сыйақы (UCM, 2004): көптеген склерозда қоршаған орта факторы ретінде адамның герпес вирусы 6-мен байланысын зерттеу.

Ғылыми қоғамдарға мүшелік

Quironsalud Мадридтегі Нейроғылымдар бойынша ұлттық және халықаралық жетекші зерттеуші (маусым 2015 – қазіргі уақытқа дейін)

Мадридтегі Quironsalud Университеттік Ауруханасының Зерттеу Комитетінің Президенті (2012 жылдан қазіргі уақытқа дейін).

Сан-Карлос Клиникалық Ауруханасының Зерттеу Комитетінің мүшесі (2012-2015).

Мадридтегі Complutense университетінің Медицина факультетінің Кеңес мүшесі (2011-2015).

Зерттеу және оқыту

100 ұлттық және халықаралық клиникалық сынақтардың бас зерттеушісі.

Carlos III Денсаулық Институтының 7 FIS зерттеу жобасы (соңғы 5 бас зерттеуші ретінде).

Жеке қорлардан 10 жоба, бәсекеге қабілетті негізде алынған (7 бас зерттеуші ретінде).

Ол 949,917 жалпы әсер ету факторына және 4,552 сілтеме иеленген 139 халықаралық мақаланың авторы. H-факторы 34 (2018) болған 38 кітап пен кітап тараулары бар.

Оның басылымдары зерттеулерге ең ғаламдық әсер ететін журналдарда ерекшеленіп тұрады, мысалы, New England Journal of Medicine және Lancet.

Др. Рафаэль Арройо түрлі Конгрестерде 300-ден астам халықаралық және ұлттық баяндамалар жасаған.

Білім :

Мадридтегі Еуропалық Университеттің Биомедициналық Ғылымдар факультетінің Медицина профессоры және Медицина Ғылымдары Профессорының ұлттық аккредитациясына ие (ANECA-дан берілген).

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Dr. Turgay Abay is an experienced neurologist with a strong background in adult and pediatric neurology. He has more than 10 years of experience diagnosing and treating a wide range of neurological conditions.

He completed specialist training in neurology at Gaziantep University (2008–2013). The university is a well-established Turkish institution known for high academic standards and clinical excellence. He then practiced at Siirt State Hospital (2013–2014), treating a broad range of neurological disorders in a public hospital.

Dr. Halil Can is a Professor of Neurosurgery (2025; Associate Professor 2020). He completed neurosurgical training at Istanbul University–Istanbul Faculty of Medicine in 2007. His clinical focus includes endoscopic and microsurgical spine surgery for fractures, tumors, and degenerative disease; advanced pain procedures; endoscopic skull base and pituitary surgery; and neurovascular, neuro-oncologic, and peripheral nerve surgery.

He has 21 international peer-reviewed papers (SCI/SSCI). Topics include cadaveric morphometry of Kambin’s triangle and the transforaminal triangular working zone, lumbar arterial and anterior approach anatomy, and an in vitro test of a new lumbar fixation device.

His clinical studies include a single-team series of 81 posterior circulation aneurysms, with 13 flow-diversion cases. He also reported five spinal cavernous malformation cases. He conducted Phase I safety and feasibility stem-cell trials in pediatric hypoxic-ischemic encephalopathy and in chronic complete spinal cord injury.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Under his leadership, the hospital is actively expanding its services, including paediatric cardiology and intensive care, and is planning to establish an interdisciplinary center for parents and children on the basis of the Department of Paediatrics.

Dr. Propson's many years of experience have established him as a leading expert in neonatology and paediatric cardiology in Germany and Europe. His dedication and commitment to the highest level of care for young patients is reflected in his work. Dr. Propson's research and scientific publications demonstrate his in-depth knowledge and commitment to development in paediatrics.

For many years Dr. Propson worked as a leading physician in the Department of Paediatrics and Adolescent Medicine at the Leverkusen Clinic in Leverkusen, Germany, where he was also responsible for managing the paediatric intensive care unit. In addition to his primary work, Dr. Propson devotes a great deal of time to continuing education to ensure that his patients receive the most up-to-date treatments in his department.

His unique professional qualities and qualifications set him apart from other physicians. Dr. Propson's patients can rest assured that they are in good hands at the Department of Paediatrics and Adolescent Medicine at the Academic Hospital Solingen.

Membership in societies:

German Association of Physicians

Expert of scientific journals

Specialisations:

Emergency medicine

Intensive care

Paediatric cardiology

Neonatology

Work Experience:

2006: Graduation from the Faculty of Medicine

2006 - 2011: Specialization as a specialist in paediatrics and adolescent medicine.

2011 - 2023: Lead physician in the Department of Paediatrics and Adolescent Medicine at the Leverkusen Clinic.

2023: Chief physician in the Department of Paediatrics at the Academic Hospital Solingen.

In 2007 he joined the Costa del Sol Hospital and left this position when he obtained an international scholarship that would take him back to San Francisco. In 2010 he moved to Japan to complete his training in the submucosal endoscopic dissection technique that he would later on introduce in Andalusia in 2011, thus becoming one of the pioneers in the performance of this technique in Spain. In 2011 he became the first medical professional in the world to use the 15-mm AXIOS stent in pancreatic fluid collection drainage. In 2018 he began to perform gastroenteroanastomosis with luminal apposition stent in patients with pancreatic cancer and bowel obstruction, thus becoming a pioneer in Andalusia to perform such technique.

He is a coauthor of the reference guides of the European Society of Gastrointestinal Endoscopy on the endoscopic treatment of chronic pancreatitis and non-variceal gastrointestinal haemorrhage.

Professional Experience

Over 24 years' experience

1999 - Degree in Medicine and Surgery. Malaga University, Spain.

2003 to 2006 - Medical Residency in the Digestive System at the Virgen Macarena Hospital in Seville, Spain.

2006 - International Scholar at the California Pacific Medical Center in San Francisco, USA.

2007 – Digestive System Specialist at the Costa del Sol Hospital, Marbella. Spain.

2008 - California Pacific Medical Center in San Francisco, USA.

2009 - Top Reviewer Award received from the Gastrointestinal Endoscopy Journal.

2011 – Pioneer in Spain in the introduction of the submucosal endoscopic dissection technique.

2011 – First professional in the world to use the AXIOS (15mm) stent for pancreatic fluid collection drainage.

2016 - Gold Medal of the Andalusian Society for Digestive Disease (SAPD, in its Spanish abbreviation).

2017 - Fellow of the American College of Gastroenterology (FACG).

2018 - Pioneer in Andalusia to perform gastroenteroanastomosis with luminal apposition stent to treat bowel obstruction.

2019 - Fellow of the American Society for Gastrointestinal Endoscopy (FASGE).

The Digestive System Unit of the Quirónsalud Marbella Hospital offers a patient service portfolio that includes all the clinical aspects of gastroenterology, hepatology, biliary duct and pancreatic disease, as well as the diagnostic and treatment techniques used in this speciality such as abdominal ultrasound, endoscopy and other functional tests.

Our specialists have solid professional backgrounds and the team is highly qualified for the diagnosis and treatment of complex diseases such as conditions related to acidity (gastric ulcers, helicobacter pylori, gastroesophageal reflux disease), enteropathies (Crohn's Disease, ulcerative colitis; coeliac disease...), viral hepatitis, hepatic cirrhosis, pancreatic disease...

The Digestive System Unit of the Quirónsalud Marbella Hospital is a pioneer in the implementation of a specific check-up programme for digestive disease with special attention to the diagnosis and treatment of colon precancerous lesions.

Diseases, treatments and techniques:

• Diagnostic and therapeutic endoscopic ultrasound

• Endoscopic resection techniques (mucosectomy/submucosal dissection)

• Submucosal or third-space endoscopy (POEM and variants)

• Bariatric endoscopy (Apollo Method)

Dr. Cheon Won Seok is the Director of the Department of Gastroenterology at Naeun Hospital. His expertise includes gastrointestinal diseases; upper gastrointestinal endoscopy and colonoscopy; polypectomy; ESD (Endoscopic Submucosal Dissection); small-bowel capsule endoscopy; digestive disorders; gastric and esophageal cancer; Helicobacter pylori infection; liver diseases; and inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.

He graduated from Kyung Hee University College of Medicine. He completed his internship at Kyung Hee Medical Center and his internal medicine residency at Hallym University Sacred Heart Hospital. He later served as a Clinical Instructor in Gastroenterology at Chung-Ang University Hospital. He is a full member of the Korean Association of Internal Medicine and a life member of the Korean Society of Gastrointestinal Endoscopy. He is also a board-certified subspecialist in gastrointestinal endoscopy and serves as a medical advisor to KBS, MBC, SBS, JTBC, and MBN.

Dr Romero Imbroda is an academic of the Royal Academy of Medicine of Eastern Andalusia and a Fellow of the European Board of Neurology, as well as a Member of the Board of Directors of the

Andalusian Society of Neurology. He combines his medical practice with his teaching role at the University of Granada, where he is a Lecturer and has been a Member of the Internal Residential Doctor Assessment Committee in Melilla until 2017.

He is the author of several national and international scientific publications. He has also participated in research projects associated with treatments for multiple sclerosis.

Professional Experience:

• 2020: President of the Andalusian Society of Neurology

• 2019: Head of the Units at the Quirónsalud Malaga and Marbella Hospitals

• 2017-2021: Neurologist at the Regional Malaga University Hospital.

• 2016-2017: Lecturer at the University of Granada.

• 2009-2017: Neurologist at the Imbrain Neuroscience Clinic. Melilla.

• 2009-2017: Neurologist at the Melilla Hospital.

• 2008-2009: Neurologist at the Virgen de las Nieves Hospital. Granada.

• 2004-2008: Neurologist at the Carlos Haya Hospital. Malaga.

Academic Training:

• 2017: Innovation and Leadership in Neurology. Business Institute. Madrid.

• 2014: Educational Commission for Foreign Medical Graduates. United States.

• 2011-2012: Management of Integrated Health Services. ESADE. Madrid.

• 2010: Neurologists for the Future. Spanish Neurology Society.

• 2010: Master in Tissue Engineering. University of Granada.

• 2010: Doctorate at the University of Granada. Summa Cum Laude. 2010.

• 2004-2008: Neurology specialist at the Carlos Haya Hospital. Malaga.

• 1997-2003: University Graduate in Medicine at the University of Granada.

The Neurology Unit of the Quirónsalud Marbella Hospital specialises in the study and treatment of conditions associated to the nervous system, the brain, the spinal cord, the peripheral nerves and the muscles. We have the most advanced technology that enables us to make accurate and personalised diagnoses and treatments in the study of patients with complex diagnoses and treatments (MRI, CT scan,electroencephalogram, transacranial doppler ultrasound, cerebral arteriogramand neuropschycological testing).

We offer our patients highly-specialised treatments for cerebrovascular and neuromuscular diseases, Parkinson's Disease, headaches and migraine, epilepsy, multiple sclerosis, peripheral neuropathies, infections of the nervous system, movement disorders, dementia and other cognitive conditions, paediatric neurology, sleep disorders, tumours and complications deriving from injuries to the spine and the head.